Nufarm prunes costs, plants diversification
Nufarm (ASX:NUF) has announced its full-year financial results for FY24, reporting a drop in net debt by 25% to $635m.
Neuren launches $50m share buy-back
Neuren Pharmaceuticals (ASX:NEU), an Australian biotech focused on developing treatments for neurological disorders, has ...